Syncor announces first U.S. I-125 seed user

Radiopharmaceutical provider Syncor has announced that the University of Kentucky Chandler Medical Center in Lexington, KY, has become the first U.S. institution to use the vendor’s PharmaSeed Iodine-125 brachytherapy seeds for the treatment of localized prostate cancer. The first I-125 brachytherapy procedures outside the U.S. were performed in March in Thailand, according to the Woodland Hills, CA-based firm.

By AuntMinnie.com staff writers
July 26, 2000

Related Reading

Syncor brachytherapy seeds cleared by FDA, January 12, 2000.

Copyright © 2000 AuntMinnie.com

Copyright © 2000 AuntMinnie.com

Page 1 of 92
Next Page